China: AstraZeneca/Junshi anti-PD-1 Tie-Up; New UK Biologics Plan for Pharmaron; Clover’s $230 Million Investment Boost


The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment news on Clover Biopharmaceuticals, Sciwind Biosciences, and Gensciences.


AstraZeneca signs deal with Chinese biotech Junshi Biosciences to market anti-PD-1 cancer drug in China

AstraZeneca has signed a deal with Chinese biotech, Junshi Biosciences to market its anti-PD-1 cancer drug, toripalimab, for urothelial carcinoma across China, and other cancer types in some areas. The two companies are also evaluating further commercial cooperation in emerging markets.


China’s Pharmaron takes UK biologics plant off AbbVie’s hands

HK-listed Pharmaron, who has an integrated cell and gene therapy platform, has entered into a definitive agreement to acquire the Allergan Biologics site in Liverpool, UK for USD 118.7M in cash from AbbVie.


Innoforce and dMed collaborate to accelerate the development of innovative therapeutics

The companies associated with the Innoforce and dMed collaboration will be housed on the Innoforce campus in Hangzhou. Central to the campus is Innforce CGTx Services, a CDMO which provides commercially capable manufacturing platforms for gene and cell therapy products, and a biopharmaceutical manufacturing facility that supplies large-molecule drugs globally through Thermo Fisher Biopharma Services (Hangzhou) LTD, a joint venture between Innoforce and Thermo Fisher.


UK-based Abcam Expands Presence in China to Support Increased Demand of BioPharma Sector

Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the expansion of its footprint in China with the opening of new custom-built facilities in Hangzhou and Shanghai. Expanded customer service, logistics and manufacturing capabilities are strengthening Abcam’s position as a leading collaborator for academia and industry in the region.


Vaccine Startup Clover Biopharma Raises $230 Million in Financing

China’s Covid-19 vaccine developer Clover Biopharmaceuticals raised $230 million in Series C financing from a group of investors led by Singapore state fund Temasek and GL Ventures. This financing round brings the Chengdu-based startup’s total capital raised in the past 12 months to more than $400 million. Other investors include Oceanpine Capital, OrbiMed and existing investor Delos Capital.


Biologics start-up Sciwind Biosciences secures USD 37 Series B funding

Sciwind Biosciences Co., Ltd. (Sciwind), a clinical-stage fast-growing biopharmaceutical company focusing on research and development of innovative biologics, has announced the closing of a $37 Million Series B financing. The financing was led by LYFE Capital and joined by the existing investors, Legend Capital and Haibang Venture Capital.


Merck and GPHL Collaborate on Business Innovation and Development in the Greater Bay Area

Merck, a leading science and technology company, today signed a Memorandum of Understanding (MOU) to begin strategic collaboration with Guangzhou Pharmaceutical Holdings Limited (GPHL), China’s leading pharmaceutical company. The collaboration aims to explore in the areas including new business model innovation, pipeline innovation and market expansion, drawing on the unique development opportunities for the biopharma industry in the Guangdong-Hong Kong-Macao Greater Bay Area.


CanSino submits COVID-19 vaccine to Chinese regulators

CanSino says their single-dose Covid-19 vaccine is 65.28% effective at preventing symptomatic Covid-19 cases, and they’ve officially filed for authorization with China’s National Medical Products Administration.


Chinese biopharma startup Gensciences lands USD 123M funding in series A, B rounds

Founded in 2019, Gensciences develops drugs that focus on underserved illnesses like hemophilia, metabolic diseases, and anti-tumor fields. It is developing coagulation factor products, as well as insulin and Glucagon-like peptide 1 (GLP-1).

Related Content

Latest Report